Polyneuropathy Temporally Associated with Tirzepatide Use in Patients with Pre-Existing Risk Factors: Two Cases
SVOA Neurology · 05.08.2026 · 7 (4) · 170-173
DOI: 10.58624/svoane.2026.07.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift SVOA Neurology, online erschienen am 05.08.2026. Verfasst von Hira Shakeel und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Tirzepatide, a GLP-1 receptor agonist, used in the treatment of diabetes and weight loss is found to be associated with polyneuropathy. We encountered two cases with multiple co-morbidities in our clinical practice who were started on tirzepatide, and they reported neuropathic symptoms afterwards. Peripheral neuropathies are attributed to different factors like metabolic, endocrine and autoimmune conditions. Through these 2 cases, we tried to evaluate the link between onset, progression and continuity of neuropathy after commencement of tirzepatide.
Zitieren
APA
Shakeel, H., & Khalid, E. (2026). Polyneuropathy Temporally Associated with Tirzepatide Use in Patients with Pre-Existing Risk Factors: Two Cases. SVOA Neurology, 7(4), 170-173. https://doi.org/10.58624/svoane.2026.07.025
Vancouver
Shakeel H, Khalid E. Polyneuropathy Temporally Associated with Tirzepatide Use in Patients with Pre-Existing Risk Factors: Two Cases. SVOA Neurology. 2026;7(4):170-173. doi:10.58624/svoane.2026.07.025
BibTeX
@article{Shakeel2026,
author = {Shakeel, Hira and Khalid, Ehtesham},
title = {Polyneuropathy Temporally Associated with Tirzepatide Use in Patients with Pre-Existing Risk Factors: Two Cases},
journal = {SVOA Neurology},
year = {2026},
volume = {7},
number = {4},
pages = {170--173},
doi = {10.58624/svoane.2026.07.025}
}
EUVIMED